Yoshimine Kohei, Tobino Kazunori, Obata Yumi, Sogabe Shouta, Uchida Kazuki, Murakami Yosuke, Yamamoto Ryuta
Respiratory Medicine, Iizuka Hospital, Fukuoka, JPN.
Cureus. 2024 Sep 1;16(9):e68400. doi: 10.7759/cureus.68400. eCollection 2024 Sep.
Trousseau's syndrome is a cancer-associated thromboembolism that significantly impacts patients' prognosis and quality of life (QOL). This study aimed to investigate the frequency, characteristics, and prognosis of Trousseau's syndrome in lung cancer patients at a Japanese community hospital and examine the effects of therapeutic agents on this condition. We retrospectively reviewed the electronic medical records of lung cancer patients diagnosed with thrombotic complications at the time of diagnosis in our department between August 2013 and April 2019. Patients' characteristics, thromboembolism sites, treatments, and prognosis were analyzed. Among 956 lung cancer patients, 19 (2%) had Trousseau's syndrome. The median age was 65 years, and adenocarcinoma was the most common histologic type (78.9%). The most common site of thromboembolism was the brain (84.2%). The median survival time was 84 days, and 52.6% of patients died within 90 days of diagnosis. Patients who survived longer than 90 days tended to have a higher frequency of non-adenocarcinoma histology, gene mutations, and therapeutic induction with immune checkpoint inhibitors (ICI). Trousseau's syndrome in lung cancer patients is associated with poor prognosis. Histologic type, mutation status, and treatment with ICI may influence the prognosis. Future larger-scale studies are needed to validate these potential prognostic factors and to develop personalized treatment strategies.
特鲁索综合征是一种与癌症相关的血栓栓塞症，严重影响患者的预后和生活质量（QOL）。本研究旨在调查日本一家社区医院肺癌患者中特鲁索综合征的发生率、特征和预后，并研究治疗药物对该病症的影响。我们回顾性分析了2013年8月至2019年4月在我院确诊时伴有血栓形成并发症的肺癌患者的电子病历。分析了患者的特征、血栓栓塞部位、治疗方法和预后情况。在956例肺癌患者中，19例（2%）患有特鲁索综合征。中位年龄为65岁，腺癌是最常见的组织学类型（78.9%）。血栓栓塞最常见的部位是脑（84.2%）。中位生存时间为84天，52.6%的患者在诊断后90天内死亡。存活超过90天的患者非腺癌组织学、基因突变和免疫检查点抑制剂（ICI）治疗诱导的频率往往更高。肺癌患者的特鲁索综合征与预后不良相关。组织学类型、突变状态和ICI治疗可能影响预后。未来需要进行更大规模的研究来验证这些潜在的预后因素，并制定个性化的治疗策略。
